Innova Captab Ltd

The provided transcript does not explicitly mention any current or future plans for fundraising through debt or equity by Innova Captab Limited. Key points related to financial plans include: - Capex guidance focuses primarily on the new R&D plant in Panchkula with Rs 10-15 crores expenditure this year. - Jammu facility capex is mostly completed; future capex limited to 3-4% maintenance until new manufacturing facilities are planned. - No explicit mention of plans for raising funds via debt or equity. - Company expects to fund growth from existing operations and capital investments without indicating external fundraising. Therefore, as per the available information, there is no indication of current or upcoming fundraising through debt or equity.

- The R&D capex for the new R&D center in Panchkula, Haryana, is already committed with an expenditure of Rs 10-15 crores expected this year. - The Jammu facility's major capex is mostly completed with about Rs 450 crores invested so far. - Future capex, apart from maintenance, will only be undertaken when planning for a new manufacturing facility; currently, maintenance capex is estimated at 3-4% of the gross block. - The Jammu greenfield expansion is progressing as planned, expected to commercialize in Q2 FY25, with revenue starting from Q3 FY25. - Jammu unit will have four independent manufacturing blocks, enhancing the product portfolio and capacity. - Long-term, the Jammu plant has asset potential to generate up to Rs 2,000 crores in topline at 40-50% utilization, targeting Rs 800-900 crores in 3-4 years. - No additional major capex is planned until the next facility is announced.

- The company expects to maintain a strong growth trajectory, aiming to double revenue and bottom-line over the next 3-4 years, driven primarily by the new Jammu facility. - Jammu plant is projected to generate Rs 800-900 crores of sales in 3-4 years, with revenue start anticipated from Q3 FY25. - The Jammu facility is expected to deliver better-than-Rs 200-300 crores revenue in FY25. - Regular business (excluding Jammu) is expected to grow in the early teens percentage range due to capacity constraints. - Overall blended growth for the current year is estimated between 12%-15%, with margins expected to remain at similar levels. - Trade generics business aims to double within 3 years, maintaining its current ~17% share. - Expansion of product categories and R&D investment supports long-term volume and revenue growth.

- Innova Captab Limited aims to double its revenue and bottom-line numbers in the next 3 years, aided by the new Jammu plant commissioning in Q2 FY25. - Jammu facility is expected to generate Rs 800-900 crores in sales over 3-4 years, contributing significantly to growth. - Revenue from Jammu might start from Q3 FY25 with margin improvement becoming noticeable from the second year onwards. - Regular business excluding Jammu anticipates early teens percentage growth due to capacity constraints, with most volume growth coming from Jammu. - Overall business expects blended growth around 12%-15% for the current year and potential margin stability around 15%. - The company targets sustainable long-term growth through capacity expansion, new R&D center in Panchkula, and increased geographical and product reach. - EBITDA margins remain steady historically in the 14%-16% range. - Focus on value-added products and compliance with regulatory standards to capture increased CDMO demand post Schedule M enhancements.

- The transcript does not explicitly state the current or expected order book or pending orders for Innova Captab Limited. - However, the company expects strong growth from the Jammu facility, aiming for Rs 800-900 crores in revenues over the next 3-4 years. - The Jammu plant is anticipated to start commercial operations by Q2 FY25, with revenues kicking in from Q3 FY25. - Domestic CDMO business inquiries are increasing, partly driven by regulatory changes like Schedule M compliance leading to industry consolidation. - The company services over 190 clients including top pharma companies, reflecting a healthy demand pipeline. - With expansion and product development initiatives (new R&D center and Jammu facility), they foresee sustained growth and an increase in order inflows going forward.